NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $675,709 | -55.7% | 85,968 | -43.7% | 0.00% | – |
| Q2 2023 | $1,525,133 | -18.7% | 152,666 | -27.7% | 0.00% | – |
| Q1 2023 | $1,876,255 | -35.0% | 211,290 | -19.6% | 0.00% | – |
| Q4 2022 | $2,885,621 | +1.0% | 262,807 | +19.9% | 0.00% | – |
| Q3 2022 | $2,856,000 | +101.1% | 219,179 | +95.5% | 0.00% | – |
| Q2 2022 | $1,420,000 | -66.1% | 112,100 | -62.5% | 0.00% | -100.0% |
| Q1 2022 | $4,187,000 | +128.4% | 298,883 | +372.3% | 0.00% | – |
| Q4 2021 | $1,833,000 | +17.4% | 63,279 | +21.4% | 0.00% | – |
| Q3 2021 | $1,561,000 | +16.1% | 52,106 | +2.8% | 0.00% | – |
| Q2 2021 | $1,344,000 | +345.0% | 50,671 | +451.7% | 0.00% | – |
| Q4 2020 | $302,000 | -96.5% | 9,184 | -96.3% | 0.00% | -100.0% |
| Q3 2020 | $8,560,000 | – | 245,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |